Alkaline phosphatase in metastatic castration-resistant prostate cancer: reassessment of an older biomarker

被引：59
|
作者：
Heinrich, Daniel [1 ]
Bruland, Oyvind [2 ]
Guise, Theresa A. [3 ]
Suzuki, Hiroyoshi [4 ]
Sartor, Oliver [5 ,6 ]
机构：
[1] Akershus Univ Hosp, Dept Oncol, Sykehusveien 25, N-1478 Lorenskog, Norway
[2] Oslo Univ Hosp, Dept Oncol, Norwegian Radium Hosp, Ullernchausseen 70, N-0379 Oslo, Norway
[3] Indiana Univ Sch Med, Dept Med, 980 W Walnut St,Walther Hall,R3,Room C130, Indianapolis, IN 46202 USA
[4] Toho Univ, Dept Urol, Sakura Med Ctr, 564-1 Shimazu, Sakura, Chiba 2858741, Japan
[5] Tulane Canc Ctr, Dept Med, 1430 Tulane Ave,SL-42, New Orleans, LA 70112 USA
[6] Tulane Canc Ctr, Dept Urol, 1430 Tulane Ave,SL-42, New Orleans, LA 70112 USA
来源：
FUTURE ONCOLOGY | 2018年 / 14卷 / 24期
关键词：
alkaline phosphatase; biomarker; bone metastases; castration-resistant prostate cancer; mechanism of action; prognostic marker; survival; BONE METASTASES; SIPULEUCEL-T; ABIRATERONE ACETATE; ANDROGEN RECEPTOR; PROGNOSTIC MODEL; DOUBLE-BLIND; 1ST-LINE CHEMOTHERAPY; RADIUM-223; DICHLORIDE; EXPLORATORY ANALYSIS; SKELETAL METASTASES;
D O I：
10.2217/fon-2018-0087
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Since most patients with metastatic castration-resistant prostate cancer (mCRPC) have bone metastases, it is important to understand the potential impact of therapies on prognostic biomarkers, such as ALP. Clinical studies involving mCRPC life-prolonging agents (i.e., sipuleucel-T, abiraterone, enzalutamide, docetaxel, cabazitaxel, and radium-223) have shown that baseline ALP level is prognostic for overall survival, and may be a better prognostic marker for overall survival than prostate-specific antigen in patients with bone-dominant mCRPC. Mechanism of action differences between therapies may partly explain ALP dynamics during treatment. ALP changes can be interpreted within the context of other parameters while monitoring disease activity to better understand the underlying pathology. This review evaluates the current role of ALP in mCRPC.
引用
收藏
页码：2543 / 2556
页数：14
相关论文
共 50 条
  • [1] Early alkaline phosphatase dynamics as biomarker of survival in metastatic castration-resistant prostate cancer patients treated with radium-223
    van der Doelen, Maarten J.
    Stockhaus, Agnes
    Ma, Yuanjun
    Mehra, Niven
    Yachnin, Jeffrey
    Gerritsen, Winald R.
    Nilsson, Sten
    van Oort, Inge M.
    Ullen, Anders
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2021, 48 (10) : 3325 - 3334
  • [2] Early alkaline phosphatase dynamics as biomarker of survival in metastatic castration-resistant prostate cancer patients treated with radium-223
    Maarten J. van der Doelen
    Agnes Stockhaus
    Yuanjun Ma
    Niven Mehra
    Jeffrey Yachnin
    Winald R. Gerritsen
    Sten Nilsson
    Inge M. van Oort
    Anders Ullén
    European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48 : 3325 - 3334
  • [3] Metastatic castration-resistant prostate cancer
    Henriques, Vanessa
    Wenzel, Mike
    Demes, Melanie-Christin
    Koellermann, Jens
    PATHOLOGE, 2021, 42 (04): : 431 - 438
  • [4] Olaparib in Metastatic Castration-Resistant Prostate Cancer
    Biswas, Bivas
    Ganguly, Sandip
    Ghosh, Joydeep
    NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (12): : 1174 - 1175
  • [5] Biomarkers in Metastatic Castration-resistant Prostate Cancer
    Miller, K.
    AKTUELLE UROLOGIE, 2015, 46 (01) : 66 - 70
  • [6] Olaparib in metastatic castration-resistant Prostate Cancer
    Lorenz, Judith
    AKTUELLE UROLOGIE, 2022, 53 (02)
  • [7] Olaparib for Metastatic Castration-Resistant Prostate Cancer
    de Bono, J.
    Mateo, J.
    Fizazi, K.
    Saad, F.
    Shore, N.
    Sandhu, S.
    Chi, K. N.
    Sartor, O.
    Agarwal, N.
    Olmos, D.
    Thiery-Vuillemin, A.
    Twardowski, P.
    Mehra, N.
    Goessl, C.
    Kang, J.
    Burgents, J.
    Wu, W.
    Kohlmann, A.
    Adelman, C. A.
    Hussain, M.
    NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (22): : 2091 - 2102
  • [8] Advances in metastatic castration-resistant prostate cancer
    Kentepozidis, Nikolaos
    INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, 2014, 34 : S108 - S108
  • [9] Rucaparib in castration-resistant, metastatic prostate cancer
    Lorenz, Judith
    AKTUELLE UROLOGIE, 2024, 55 (02) : 96 - 98
  • [10] Management of Metastatic Castration-Resistant Prostate Cancer
    Srinivas, Sandy
    JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2021, 19 (5.5): : 614 - 616
12345